ClinicalTrials.gg
Active, not recruitingNCT07427797LAURITE 1Updated Sep 9, 2026

A Study to Assess the Effectiveness and Safety of IPN10200 in Adults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows

A Phase 3 interventional study of Corabotase and Placebo in Moderate to Severe Glabellar Lines, sponsored by Ipsen. Active, not recruiting at 23 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-09.

Sponsored by Ipsen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
309
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to assess the effectiveness and safety of Corabotase (also known as IPN10200) compared to placebo in the improvement of the appearance of moderate to severe glabellar lines in adult participants. Glabellar lines are wrinkle-like lines that appear between the eyebrows and can become more noticeable with age or repeated facial expressions. They may affect a person's appearance and confidence.

In this study, all participants will receive a single injection of either Corabotase or placebo (the study drug). There will be 3 periods in this study:

  • A screening period (up to 20 days) to assess whether the participant can take part, requiring at least 1 visit to the study centre.
  • A treatment period (Day 1) where all the eligible participants will receive a single injection of IPN10200 or placebo.
  • A follow-up period (52 weeks) where participants' health will be monitored, consisting of regular visits to the study centre and 1 telephone call visit.

Participants will undergo health measurements and observation, including blood sampling, physical examinations, clinical evaluations and electrocardiograms (ECG: recording of the electrical activity of heart). They will also be asked to fill in questionnaires and keep a diary. Each participant will be in this study for up to 55 weeks. Participants may withdraw consent to participate at any time.

02

Conditions studied

  • Moderate to Severe Glabellar Lines
03

In context

Lead sponsor

Ipsen is the lead sponsor of 289 studies on the registry; 17 are open to participants now.

Of its 26 completed or terminated interventional studies of FDA-regulated products, 22 (85%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant should be male or female, ≥18 years of age inclusive at the time of signing the ICF.
  • Moderate or severe (Grade 2 or 3) GL at MF at baseline, as assessed by the ILA using a validated 4-point photographic scale.
  • Moderate or severe (Grade 2 or 3) GL at MF at baseline, as assessed by the SSA using a 4-point categorical scale.
  • Dissatisfied or very dissatisfied (Grade 2 or 3) with their lines at baseline, as assessed by the SLS.
  • For female participants: use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
  • Capable of giving signed which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.
  • Participant has both the time and the ability to complete the study and comply with study instructions.
  • Does not reside in an institution by administrative or court order.
  • Is not a sponsor employee or clinical research unit personnel directly affiliated with the study or is not an immediate family member. Immediate family is defined as a spouse, parent, child or sibling whether biological or legally adopted.

Exclusion criteria

Exclusion Criteria:

  • An active infection or other skin problems in the upper face including the GL area (e.g. acute acne lesions or ulcers).
  • A history of eyelid blepharoplasty or brow lift or any other upper facial surgery within the past 5 years.
  • A history of facial nerve palsy.
  • Marked facial asymmetry, ptosis, excessive dermatochalasis, deep dermal scarring or thick sebaceous skin.
  • Presence of any scars, piercings or tattoos (including micro blading of the eyebrows) in or around the treatment area that have occurred within 6 months prior to baseline, or which in the investigator's opinion, could interfere with evaluations.
  • Any known medical condition that may put the participant at increased risk in regard to exposure to BoNT of any serotype (i.e. myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, etc.).
  • Administration of any BoNT (other than the study intervention on baseline visit) into any site of the body and for any indication from 9 months prior to the first study visit until the end of the study.
  • Participants who have received IPN10200 in a previous study.
  • Use of medications that affect neuromuscular transmission (such as curare-like nondepolarising agents, lincosamides, polymyxins, anticholinesterases) within the past 30 days prior to baseline are prohibited or a longer of at least five half-lives might be required, as deemed appropriate by the investigator for long-acting medications.
  • Use of aminoglycoside antibiotics within the past 30 days prior to baseline are prohibited. Note: Topical use apart from the area of injection would be acceptable.
  • Use of systemic retinoids within the past 30 days prior to baseline and planned use during the study. Note: Topical retinoids are allowed other than in the areas that will be injected (upper facial area) at the discretion of the investigator.
  • Any prior treatment with permanent fillers, lifting threads, autologous fat or permanent procedures in the upper face including the GL area.
  • Administration of any non-permanent injectables (such as hyaluronic acid, calcium hydroxylapatite, poly-L-Lactic acid or polymethyl-methacrylate) soft tissue augmentation therapy in the GL region within 12 months prior to baseline.
  • Any prior facial treatment or aesthetic procedures to the upper face including photo rejuvenation, vascular or pigment laser or microneedling within the 3 months prior to baseline.
  • Any prior facial treatment or aesthetic procedures to the upper face involving skin resurfacing (including dermabrasion, laser or whatever the interventional technique used) or chemical peel within the past 12 months prior to baseline.
  • Any planned cosmetic surgery or aesthetic procedures to the upper face during the study and/or any procedures to other parts of the face which in the investigator's opinion, could interfere with evaluations during the study.
  • Any past surgery in the UFL area including GL.
  • Planned use of concomitant therapy which, in the investigator's opinion, would interfere with the evaluation of the safety or efficacy of the study intervention. Therapy considered necessary for the participant's welfare may be given at the discretion of the investigator. Note: If the permissibility of a specific medication/treatment is in question, the medical monitor will be contacted.
  • Use of any experimental device within 30 days prior to baseline visit or use of any treatment with an experimental drug within five times the documented terminal half-life of the respective drug or its metabolites or if the half-life is unknown within 30 days prior to the start of the study (prior to baseline visit) and during the conduct of the study.
  • Known positive for antigen, virus antibody or for or a diagnosis of acquired immunodeficiency syndrome.
  • Clinically diagnosed significant anxiety disorder, or any other significant psychiatric disorder (e.g. depression) that might interfere with the participant's participation in the study.
  • An inability to substantially lessen GL as determined by the investigator.
  • Known allergy or to BoNT or any of IPN10200.
  • A history of chronic or recreational drug abuse as assessed by the investigator.
  • Any uncontrolled systemic disease or other significant medical condition which would be harmful for the participant to be entered into the study or continue participation.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
309 participants (actual)

Study arms

  • Experimental
    Corabotase group

    Participants will receive Corabotase through injections into the selected muscles on Day 1.

    Biological: Corabotase

  • Placebo comparator
    Placebo group

    Participants will receive placebo through injections into the selected muscles on Day 1.

    Biological: Placebo

Interventions

  • BiologicalCorabotase

    A single vial of lyophilised powder for solution for injection will be injected locally into several sites across the glabellar region.

  • BiologicalPlacebo

    A single vial of lyophilised powder for solution, containing excipients without active substance, will be injected locally into several sites across the glabellar region.

06

What researchers measure

Primary outcomes

  1. For North America: Percentage of participants responding to treatment

    Measured by the multicomponent response of ≥2-grade improvement from baseline and a score of 'None' or 'Mild' on Investigator's Live Assessment (ILA) and Subject's Self-Assessment (SSA) at maximum frown ILA: a validated 4-point photographic scale used to assess the severity and appearance of glabellar lines at maximum frown, where grade 0 = "None," grade 1 = "Mild," grade 2 = "Moderate," and grade 3 = "Severe." SSA: a 4-point categorical scale used to assess the appearance of glabellar lines at maximum frown, where grade 0 = "No wrinkles," grade 1 = "Mild wrinkles," grade 2 = "Moderate wrinkles," and grade 3 = "Severe wrinkles.

    Time frame: From baseline to week 4

  2. For EU and ROW: Percentage of participants responding to treatment

    Measured by a ≥2-grade improvement on Investigator's Live Assessment (ILA)at maximum frown ILA: a validated 4-point photographic scale used to assess the severity and appearance of glabellar lines at maximum frown, where grade 0 = "None," grade 1 = "Mild," grade 2 = "Moderate," and grade 3 = "Severe."

    Time frame: From baseline to week 4

Secondary outcomes

  1. For North America: Percentage of participants responding to treatment

    Measured by the multicomponent response of ≥2-grade improvement from baseline and a score of 'None' or 'Mild' on Investigator's Live Assessment (ILA) and Subject's Self-Assessment (SSA) at maximum frown. ILA: a validated 4-point photographic scale used to assess the severity and appearance of glabellar lines at maximum frown, where grade 0 = "None," grade 1 = "Mild," grade 2 = "Moderate," and grade 3 = "Severe." SSA: a 4-point categorical scale used to assess the appearance of glabellar lines at maximum frown, where grade 0 = "No wrinkles," grade 1 = "Mild wrinkles," grade 2 = "Moderate wrinkles," and grade 3 = "Severe wrinkles.

    Time frame: At week 24

  2. For EU and ROW: Response to treatment as measured by a score of 'None' or 'Mild' at Week 4 on the ILA at maximum frown

    ILA: a validated 4-point photographic scale used to assess the severity and appearance of glabellar lines at maximum frown, where grade 0 = "None," grade 1 = "Mild," grade 2 = "Moderate," and grade 3 = "Severe."

    Time frame: At week 24

  3. Percentage of participants responding to treatment as measured by a score of "None" or "Mild on ILA at maximum frown

    ILA: a validated 4-point photographic scale used to assess the severity and appearance of glabellar lines at maximum frown, where grade 0 = "None," grade 1 = "Mild," grade 2 = "Moderate," and grade 3 = "Severe."

    Time frame: At week 24

  4. Percentage of participants responding to treatment as measured by a score of "None" or "Mild on SSA at maximum frown

    SSA: a 4-point categorical scale used to assess the appearance of glabellar lines at maximum frown, where grade 0 = "No wrinkles," grade 1 = "Mild wrinkles," grade 2 = "Moderate wrinkles," and grade 3 = "Severe wrinkles.

    Time frame: At week 24

  5. For all regions except United States: Percentage of participants satisfied with their facial appearance after the treatment as measured by a score of 'Very Satisfied' or 'Satisfied' on Subject's Level of Satisfaction (SLS)

    SLS: a 4-point categorical scale used to assess satisfaction with the appearance of glabellar lines, where grade 0 = "Very satisfied," grade 1 = "Satisfied," grade 2 = "Dissatisfied," and grade 3 = "Very dissatisfied."

    Time frame: At week 4

  6. For all regions except United States: Number of participants satisfied with their facial appearance after the treatment as measured by a score of 'Very Satisfied' or 'Satisfied' on SLS

    SLS: a 4-point categorical scale used to assess satisfaction with the appearance of glabellar lines, where grade 0 = "Very satisfied," grade 1 = "Satisfied," grade 2 = "Dissatisfied," and grade 3 = "Very dissatisfied."

    Time frame: At week 24

  7. For EU: Response as measured by an improvement of ≥ 10 points from baseline on the Rasch Transformed Score of the FACE-Q Psychological Function Scale

    FACE-Q Psychological Function Scale: a validated 4-point categorical scale used to assess participants' psychological well-being. The scale consists of statements about how participants feel about themselves, with responses indicating the level of agreement on a 4-point scale ranging from "strongly disagree" to "strongly agree."

    Time frame: At week 4

  8. Percentage of participants responding to treatment as measured by a score of "None" or "Mild on ILA at maximum frown

    ILA: a validated 4-point photographic scale used to assess the severity and appearance of glabellar lines at maximum frown, where grade 0 = "None," grade 1 = "Mild," grade 2 = "Moderate," and grade 3 = "Severe."

    Time frame: From baseline to each post-treatment visit until Week 52 (except week 4 [for EU and ROW] and week 24)

  9. Percentage of participants responding to treatment as measured by a score of "None" or "Mild on SSA at maximum frown

    SSA: a 4-point categorical scale used to assess the appearance of glabellar lines at maximum frown, where grade 0 = "No wrinkles," grade 1 = "Mild wrinkles," grade 2 = "Moderate wrinkles," and grade 3 = "Severe wrinkles.

    Time frame: From baseline to each post-treatment visit until week 52 (except week 24)

  10. Percentage of participants responding to treatment

    Measured by the multicomponent response of 2-grade improvement and a score of 'None or 'Mild' on both the ILA and SSA at maximum frown. ILA: a validated 4-point photographic scale used to assess the severity and appearance of glabellar lines at maximum frown, where grade 0 = "None," grade 1 = "Mild," grade 2 = "Moderate," and grade 3 = "Severe." SSA: a 4-point categorical scale used to assess the appearance of glabellar lines at maximum frown, where grade 0 = "No wrinkles," grade 1 = "Mild wrinkles," grade 2 = "Moderate wrinkles," and grade 3 = "Severe wrinkles.

    Time frame: From baseline to each post-treatment visit until week 52 (up to 1 year), (except week 4 and 24 for North America)

  11. Percentage of participants responding to treatment as measured by the response of 2-grade improvement on ILA at maximum frown

    ILA: a validated 4-point photographic scale used to assess the severity and appearance of glabellar lines at maximum frown, where grade 0 = "None," grade 1 = "Mild," grade 2 = "Moderate," and grade 3 = "Severe."

    Time frame: From baseline to each post-treatment visit until Week 52 (up to 1 year) (except Week 4 for EU and ROW)

  12. Percentage of participants responding to treatment as measured by the response of 2-grade improvement on SSA at maximum frown

    SSA: a 4-point categorical scale used to assess the appearance of glabellar lines at maximum frown, where grade 0 = "No wrinkles," grade 1 = "Mild wrinkles," grade 2 = "Moderate wrinkles," and grade 3 = "Severe wrinkles.

    Time frame: From baseline to each post-treatment visit until Week 52 (up to 1 year)

  13. Percentage of participants responding to treatment as measured by the response of 1-grade improvement on ILA at maximum frown

    ILA: a validated 4-point photographic scale used to assess the severity and appearance of glabellar lines at maximum frown, where grade 0 = "None," grade 1 = "Mild," grade 2 = "Moderate," and grade 3 = "Severe."

    Time frame: From baseline to each post-treatment visit until Week 52 (up to 1 year)

  14. Percentage of participants responding to treatment as measured by the response of 1-grade improvement on SSA at maximum frown

    SSA: a 4-point categorical scale used to assess the appearance of glabellar lines at maximum frown, where grade 0 = "No wrinkles," grade 1 = "Mild wrinkles," grade 2 = "Moderate wrinkles," and grade 3 = "Severe wrinkles.

    Time frame: From baseline to each post-treatment visit until Week 52] (up to 1 year)

  15. Percentage of participants responding to treatment as measured by the response of 1-grade improvement on ILA at rest

    ILA: a validated 4-point photographic scale used to assess the severity and appearance of glabellar lines at rest, where grade 0 = "None," grade 1 = "Mild," grade 2 = "Moderate," and grade 3 = "Severe."

    Time frame: From baseline to each post-treatment visit until Week 52 (up to 1 year)

  16. Percentage of participants satisfied with their facial appearance after the treatment as measured by a score of 'Very Satisfied' or 'Satisfied' on SLS

    SLS: a 4-point categorical scale used to assess satisfaction with the appearance of glabellar lines, where grade 0 = "Very satisfied," grade 1 = "Satisfied," grade 2 = "Dissatisfied," and grade 3 = "Very dissatisfied."

    Time frame: From baseline to each post-treatment visit until Week 52 (up to 1 year), (except Week 4 and 24 for all regions except United States)

  17. Percentage of participants answering 'Improved', 'Much Improved' or 'Very Much Improved', as measured by Global Aesthetic Improvement Scale (GAIS) at maximum frown

    GAIS: a validated 7-point categorical scale used to assess global aesthetic improvement in appearance compared to pretreatment, as determined by the participant at maximum frown, where grade -3 = "Very much worse," grade -2 = "Much worse," grade -1 = "Worse," grade 0 = "No change," grade 1 = "Improved," grade 2 = "Much improved," and grade 3 = "Very much improved."

    Time frame: At week 1, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52 (up to 1 year)

  18. Percentage of participants answering 'Improved', 'Much Improved' or 'Very Much Improved', as measured by GAIS at rest

    GAIS: a validated 7-point categorical scale used to assess global aesthetic improvement in appearance compared to pretreatment, as determined by the participant at rest, where grade -3 = "Very much worse," grade -2 = "Much worse," grade -1 = "Worse," grade 0 = "No change," grade 1 = "Improved," grade 2 = "Much improved," and grade 3 = "Very much improved."

    Time frame: At week 1, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52 (up to 1 year)

  19. Percentage of clinicians answering 'Improved', 'Much Improved' or 'Very Much Improved', as measured by Global Aesthetic Improvement Scale (GAIS) at maximum frown

    GAIS: a validated 7-point categorical scale used to assess global aesthetic improvement in appearance compared to pretreatment, as determined by the clinician at maximum frown, where grade -3 = "Very much worse," grade -2 = "Much worse," grade -1 = "Worse," grade 0 = "No change," grade 1 = "Improved," grade 2 = "Much improved," and grade 3 = "Very much improved."

    Time frame: At week 1, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52 (up to 1 year)

  20. Percentage of clinicians answering 'Improved', 'Much Improved' or 'Very Much Improved', as measured by Global Aesthetic Improvement Scale (GAIS) at rest

    GAIS: a validated 7-point categorical scale used to assess global aesthetic improvement in appearance compared to pretreatment, as determined by the clinician with the participant at rest, where grade -3 = "Very much worse," grade -2 = "Much worse," grade -1 = "Worse," grade 0 = "No change," grade 1 = "Improved," grade 2 = "Much improved," and grade 3 = "Very much improved."

    Time frame: At week 1, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52 (up to one year)

  21. Percentage of participants with change from baseline in psychological function, as measured by Psychological Well-Being Scale on FACE-Q

    FACE-Q Psychological Function Scale: a validated 4-point categorical scale used to assess participants' psychological well-being. The scale consists of statements about how participants feel about themselves, with responses indicating the level of agreement on a 4-point scale ranging from "strongly disagree" to "strongly agree."

    Time frame: At baseline, week 1, 2, 4 (except the EU), 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52 (up to 1 year)

  22. Time to onset of treatment response based on subject diary to evaluate the appearance of their lines

    Participants record in a diary whether they notice an improvement in the appearance of their glabellar lines, with responses captured as Yes/No.

    Time frame: At baseline and daily from Day 1 to Day 8 (Week 1)

  23. Time taken for a responder to re-exhibit their baseline severity grade on the ILA at maximum frown

    Responder is defined as having a score of 'None' or 'Mild' on the ILA. ILA: a validated 4-point photographic scale used to assess the severity and appearance of glabellar lines at maximum frown, where grade 0 = "None," grade 1 = "Mild," grade 2 = "Moderate," and grade 3 = "Severe."

    Time frame: At all timepoints post-injection (Day 1) until end of study (up to 1 year)

  24. Time taken for a responder to re-exhibit a severity grade of 'Moderate' or 'Severe' as measured by the ILA at maximum frown

    Responder is defined as having a score of 'None' or 'Mild' on the ILA. ILA: a validated 4-point photographic scale used to assess the severity and appearance of glabellar lines at maximum frown, where grade 0 = "None," grade 1 = "Mild," grade 2 = "Moderate," and grade 3 = "Severe."

    Time frame: At all timepoints post-injection (Day 1) until end of study (up to 1 year)

  25. Percentage of participants experiencing treatment emergent adverse events (TEAEs)

    An Adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. TEAE is an AE for which the start date is on or after the date that the intervention began.

    Time frame: At all timepoints post-injection (Day 1) until end of study (up to 1 year)

  26. Percentage of participants experiencing serious adverse events (SAEs)

    A Serious Adverse Event (SAE) is any untoward medical occurrence that results in death, is life-threatening, requires or prolongs hospitalization, results in persistent or significant disability/incapacity, is a congenital abnormality/birth defect, or is considered medically significant by the investigator.

    Time frame: At all timepoints post-injection (Day 1) until end of study (up to 1 year)

  27. Percentage of participants experiencing Adverse Events (AEs) (or SAEs) leading to withdrawals and Adverse Events of Special Interest (AESIs)

    An Adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. TEAE is an AE for which the start date is on or after the date that the intervention began. Adverse events of special interest (AESIs) are AEs that may not be serious but are of special importance to a particular drug or class of drugs.

    Time frame: At all timepoints post-injection (Day 1) until end of study (up to 1 year)

  28. Percentage of participants with clinically significant changes from baseline in vital signs

    Clinically significant changes in vital signs will be reported. The clinical significance will be graded by the investigator.

    Time frame: At all timepoints post-injection (Day 1) until end of study (up to 1 year)

  29. Percentage of participants with clinically significant change from baseline in 12-lead Electrocardiogram (ECG) readings

    Time frame: At week 4 and week 52

  30. Percentage of participants with clinically significant change from baseline in facial examination

    Clinically significant changes in facial examination and focused neurological/physical examinations will be reported. The clinical significance will be graded by the investigator.

    Time frame: At all timepoints post-injection (Day 1) until end of study (up to 1 year)

  31. Percentage of participants with binding antibodies to IPN10200

    Time frame: At screening, week 4, 12, 24, 36 and 52 (up to 1 year 1 month)

  32. Percentage of participants with neutralising antibodies to IPN10200

    Time frame: At screening, week 4, 12, 24, 36 and 52 (up to 1 year 1 month)

07

Study locations

23 sites
  • Skin Wellness Dermatology - Homewood
    Birmingham, Alabama 35209, United States
  • Advanced Research Associates
    Glendale, Arizona 85308, United States
  • Avacare
    Scottsdale, Arizona 85260, United States
  • Investigate MD, LLC
    Scottsdale, Arizona 85260, United States
  • Ablon Skin Institute and Research Center
    Manhattan Beach, California 90266, United States
  • Keith A. Marcus, MD Inc
    Redondo Beach, California 90277, United States
  • West Dermatology
    San Diego, California 92121, United States
  • Ava T. Shamban, M.D., Inc.
    Santa Monica, California 90404, United States
  • Art of Skin MD
    Solana Beach, California 92075, United States
  • Pacific Clinical Innovations Inc.
    Vista, California 92083, United States
  • Skin Research Institute
    Coral Gables, Florida 33146, United States
  • ICON Dermatology and Aesthetics
    Bethesda, Maryland 20852, United States
  • Clinical Research Center of the Carolinas
    Charleston, South Carolina 29407, United States
  • Westlake Dermatology & Cosmetic Surgery - Westlake
    Austin, Texas 78746-5059, United States
  • Dermatology and Laser Surgery Center
    Houston, Texas 77004, United States
  • Pflugerville Dermatology Clinical Research Center, Inc. d/b/a Austin Institute for Clinical Research
    Pflugerville, Texas 78660, United States
  • SkinDC
    Arlington, Virginia 22209, United States
  • Carruthers and Humphrey Cosmetic Medicine
    Vancouver, British Columbia V5Z 4E1, Canada
  • Pacific Dermaesthetics Inc.
    Vancouver, British Columbia V6H4E1, Canada
  • Institute of Cosmetic and Laser Surgery
    Oakville, Ontario L6J 7W5, Canada
  • Sweat clinics of canada
    Toronto, Ontario M5R 3N8, Canada
  • Bertucci MedSpa
    Woodbridge, Ontario L4L 8E2, Canada
  • Centre de Recherche Dermatologique de Quebec
    Québec, Quebec G1V4X7, Canada
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants

Time frame: Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the US and/or EU.

Access criteria: Further details on Ipsen's sharing criteria and process for sharing are available here (https://www.ipsen.com/science/clinical-trials/clinical-data-transparency/).

Data sharing details ↗ · www.ipsen.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2026 (actual). Primary completion is estimated for Dec 2026, 9 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 17, 2026
First posted
Feb 23, 2026
StartActual
Feb 27, 2026
Primary completionEst.
Dec 15, 2026
CompletionEst.
Jul 15, 2027
Last update
Sep 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07427797
Lead sponsor
Ipsen
Responsible party
Sponsor
First posted
Feb 23, 2026
Start date
Feb 27, 2026
Primary completion
Dec 15, 2026 (estimated)
Completion
Jul 15, 2027 (estimated)
Last update
Sep 9, 2026

Study contacts

Ipsen Medical Director
study director · Ipsen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Corabotase

Start the discussion